Executive Committee · Board-certified hematologist-oncologist
Eduardo Braun, MD
Still seeing patients. Still reading genomes.
Board-certified hematologist and medical oncologist in active U.S. practice. Co-author of a 2017 Journal of Thoracic Oncology genomic study of pulmonary sarcomatoid carcinoma (PubMed 28315738).
ABIM Medical Oncology
ABIM Hematology
NPI 1144486309
The question a community oncologist actually asks
Not “is p53 interesting?” — it has been interesting for forty years. The questions are uglier: which patients, what toxicity, what comparator, and does this belong in a TNBC clinic that already runs on time and prior authorizations. Braun is on the committee so those questions get asked before a protocol is frozen.
A genomic paper, not a vanity byline
In 2017 he co-authored a Journal of Thoracic Oncology study showing that pulmonary sarcomatoid carcinomas often harbor targetable alterations or high tumor mutational burden (PMID 28315738, doi:10.1016/j.jtho.2017.03.005). That is the habit he brings to PHP: look at the tumor as a genome, then ask whether the drug matches it.
A practicing oncologist’s biography
Dr. Eduardo Braun is a board-certified hematologist and medical oncologist with more than 20 years of US experience, contributing frontline oncology insight to PHP Biotech’s Executive Committee.
He earned his medical degree at the Federal University of Rio de Janeiro School of Medicine and completed residency in Internal Medicine and fellowship in Hematology/Oncology at Rush University Medical Center in Chicago. He is board-certified by the American Board of Internal Medicine in medical oncology and hematology, with a focus on solid tumors.
Practicing in the greater Chicago and Northwest Indiana region, he is a co-director of Powers Health’s clinical research program and an active member of ASCO and the International Association for the Study of Lung Cancer (IASLC). His clinical perspective helps keep PHP53-nb development anchored to endpoints that matter to practicing oncologists and patients.
Licensure and literature
How to look this physician up
Everything below is meant to be checked. Empty categories are omitted rather than padded.
NPI
1144486309
National Provider Identifier, independently searchable
Boards and training
- MD, Federal University of Rio de Janeiro School of Medicine
- Residency, Internal Medicine, Rush University Medical Center
- Fellowship, Hematology/Oncology, Rush University Medical Center
- ABIM board-certified: Medical Oncology; Hematology
- NPI 1144486309
Education
- M.D., Federal University of Rio de Janeiro School of Medicine
- Internal Medicine residency, Rush University Medical Center, Chicago
- Hematology/Oncology fellowship, Rush University Medical Center, Chicago
Affiliations
- PHP Biotech International Inc. (Executive Committee)
- Northwest Cancer Centers / Powers Health (practicing oncologist; clinical research co-director)
Professional memberships
- American Society of Clinical Oncology (ASCO)
- International Association for the Study of Lung Cancer (IASLC)
Independently indexed publications
Indexed on PubMed, Crossref, or Google Patents. Internal, unpublished data is not listed as peer-reviewed work.
Peer-reviewed · 2017
Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling
Schrock AB, Li SD, Frampton GM, Suh J, Braun E, et al.
J Thorac Oncol. 2017;12(6):932-942
doi:10.1016/j.jtho.2017.03.005PMID 28315738
Co-author. Indexed on PubMed; ~194 citations (Google Scholar / PubMed citing articles).